Literature DB >> 8872415

Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset.

D L Murman1, N L Foster, S P Kilgore, C A McDonagh, J K Fink.   

Abstract

Apolipoprotein E (apoE) epsilon 4 allele frequency among Alzheimer's disease (AD) patients is increased compared to control subjects and is influenced by the presence of other genetic factors and age at symptom onset. We examined the relationship between age at AD symptom onset and apoE by comparing the apoE epsilon 4 allele frequency of normal, elderly control subjects (n = 107) to that in AD patients (n = 123), divided into four age-at-onset periods. Additionally, the distribution of symptom onset ages of AD patients with and without apoE epsilon 4 alleles was determined. We observed increased apoE epsilon 4 allele frequencies between the AD onset ages of 55 and 75 years, but not at the extremes of onset ages (i.e. onset between 45 and 54 years of age and after age 75). Our data suggests that having an apoE epsilon 4 allele increases the likelihood that AD patients will develop symptoms in the middle range of onset ages. At the extremes of AD onset ages, non-apoE factors, including other genetic factors and age, are more important determinants of risk of developing AD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872415     DOI: 10.1159/000106888

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  11 in total

Review 1.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 2.  Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities.

Authors:  Christiane Reitz
Journal:  Expert Rev Mol Diagn       Date:  2015-01-29       Impact factor: 5.225

Review 3.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

4.  Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.

Authors:  Ging-Yuek R Hsiung; A Dessa Sadovnick; Howard Feldman
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

Review 5.  Genetics of Alzheimer's disease in Caribbean Hispanic and African American populations.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

Review 6.  Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 7.  Endophenotypes in normal brain morphology and Alzheimer's disease: a review.

Authors:  C Reitz; R Mayeux
Journal:  Neuroscience       Date:  2009-04-09       Impact factor: 3.590

Review 8.  Genome-wide association studies in Alzheimer's disease: a review.

Authors:  Giuseppe Tosto; Christiane Reitz
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

9.  Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease.

Authors:  Luke W Bonham; Ethan G Geier; Chun C Fan; Josiah K Leong; Lilah Besser; Walter A Kukull; John Kornak; Ole A Andreassen; Gerard D Schellenberg; Howard J Rosen; William P Dillon; Christopher P Hess; Bruce L Miller; Anders M Dale; Rahul S Desikan; Jennifer S Yokoyama
Journal:  Ann Clin Transl Neurol       Date:  2016-08-26       Impact factor: 4.511

10.  Age-dependent effect of APOE and polygenic component on Alzheimer's disease.

Authors:  Eftychia Bellou; Emily Baker; Ganna Leonenko; Matthew Bracher-Smith; Paula Daunt; Georgina Menzies; Julie Williams; Valentina Escott-Price
Journal:  Neurobiol Aging       Date:  2020-04-30       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.